Brimhana Panchakarma Protocol (CDC-KP) In Lean Type 2 Diabetes: First Adequately Powered Analysis Of The Oil-Based Basti Arm Compared To Shodhana Protocol — A Retrospective Two-Site Study From Boisar-Palghar, Maharashtra

The Charaka Samhita, in its treatment of Prameha, makes an anatomical and therapeutic distinction that has no direct parallel in modern diabetes management. In Chikitsa Sthana 6.15–16, the text explicitly stratifies diabetic patients by body habitus: Sthula Pramehi (obese diabetics with Kapha and Medas excess) are prescribed vigorous Shodhana (bio-purificatory) therapy, while Krisha Pramehi (lean diabetics with Vata predominance and Dhatu Kshaya — tissue depletion) are prescribed Brimhana (nourishing, tissue-building) therapy.¹ This stratification is not merely a dosing adjustment — it reflects a fundamentally different understanding of the pathophysiology of lean versus obese diabetes.

This classical distinction maps remarkably well onto modern endocrinology. Lean T2DM — defined broadly as T2DM in patients with BMI <23 kg/m² by Asian criteria — is pathophysiologically distinct from obese T2DM: it is characterized primarily by insulin secretory deficiency (reduced beta-cell mass and impaired insulin pulsatility) rather than insulin resistance, is associated with a different genetic risk architecture, and has a markedly different cardiometabolic risk profile.^2,3 These patients do not benefit from the same aggressive weight-reduction strategies that define obese T2DM management — and yet they are routinely managed with identical pharmacological protocols.

The CDC-KP protocol operationalizes the classical Brimhana approach for lean diabetics. Its defining feature is Anuvasana Basti — an oil-based per-rectal therapy using a medicated preparation of Gudmar (Gymnema sylvestre), Daru Haridra (Berberis aristata), and Yashti Madhu (Glycyrrhiza glabra). Unlike the Kwath (decoction)-based Basti used in CDC-SP, the Anuvasana oil-based preparation provides lipid-soluble carriers for fat-soluble phytoconstituents, offers nourishing (Brimhana) action to the enteric mucosa and Dhatus (body tissues), and pacifies the Vyana Vata and Apana Vata disturbances that underlie lean diabetic pathology.⁴

Despite CDC-KP being a distinct protocol arm in clinical deployment across Madhavbaug's clinic network, all published and unpublished analyses have faced a critical limitation: CDC-KP cohort sizes of n=2–11 across individual clinic datasets provide insufficient statistical power to draw valid conclusions about the arm's efficacy or to meaningfully compare it against CDC-SP. As a result, the Ayurvedic classical prediction — that lean diabetics respond primarily with glycemic improvement while showing minimal anthropometric change — has remained clinically unverified in the CDC protocol context.

The Boisar-Palghar combined dataset is exceptional in this regard: with CDC-KP n=24 and CDC-SP n=30 from two adjacent clinics in Palghar District, Maharashtra, it provides the first adequately powered head-to-head comparison of both arms. This study reports those results.

2. MATERIALS AND METHODS

2.1 Study Design and Setting

Retrospective observational study from two clinic sites in Palghar District, Maharashtra: (1) Madhavbaug Clinics, Boisar branch (n=42 patients) and (2) Madhavbaug Clinics, Palghar branch (n=14 patients). Both sites implemented the same CDC protocol under the same clinical supervision structure. Boisar is an industrial town on the Konkan coast with mixed industrial and agricultural demographics; Palghar is the district headquarters with a predominantly mixed urban-rural population. Data were extracted from electronic patient records. The study was conducted in accordance with the Declaration of Helsinki.

2.2 Study Participants

T2DM patients who completed at least one CDC protocol cycle with documented pre- and post-treatment parameters were included. Assignment to CDC-SP or CDC-KP was determined by baseline BMI using the Asian cutoff of 23 kg/m²: BMI ≥23 → CDC-SP; BMI <23 → CDC-KP. Two patients (DM-HTN protocol) were included in the overall cohort but excluded from the primary SP vs. KP comparative analysis. Final analytic cohort: n=56 (CDC-SP n=30, CDC-KP n=24, DM-HTN n=2). Comorbidities included hypertension (n=7), dyslipidemia (n=6), hypothyroidism (n=2), CAD with DVD (n=1).

2.3 Intervention Protocol

2.3.1 Shared Components (Both Arms)

Snehan: Full-body Abhyanga with Neem Siddha Taila (Azadirachta indica-processed medicated oil). Cutaneous absorption and parasympathomimetic massage stimulation.

Swedan: Medicated steam with Dashmula Kwath (decoction of ten classical roots). Promotes metabolic clearance of Ama and peripheral circulation.

Prameha Diet Box: Standardized 800 kcal/day ready-to-use meal (low carbohydrate, high protein, moderate fat) aligned with DiRECT trial principles⁵ and Ayurvedic Prameha dietary guidelines.

Individualized Herbal Medication: Oral herbal prescriptions individualized by treating physician based on Prakriti, Vikriti, and comorbidity profile.

2.3.2 Differentiating Feature: Basti Formulation

The critical distinction between CDC-SP and CDC-KP is the Basti preparation:

CDC-SP Basti (Niruha/Kashaya Basti): Kwath (decoction)-based preparation of Gudmar (Gymnema sylvestre), Daru Haridra (Berberis aristata), and Yashti Madhu (Glycyrrhiza glabra). Water-soluble active constituents — gymnemic acids, berberine, glycyrrhizin — are absorbed via the colonic mucosa into portal circulation. This formulation exerts Shodhana (purificatory) and Ruksha (drying) action, reducing Kapha-Meda accumulation.

CDC-KP Basti (Anuvasana/Sneha Basti): Oil-based preparation using the same three herbs — Gudmar, Daru Haridra, and Yashti Madhu — processed in a lipid carrier. The oil base provides:

• Brimhana (nourishing) action — counteracting the Dhatu Kshaya (tissue depletion) of Krisha Pramehi
• Vata Anulomana — restoring the normal downward movement of Apana Vata, governing pancreatic secretory function
• Lipid-soluble carrier — potentially enhancing bioavailability of fat-soluble phytoconstituents (terpenoids, sterols) from the three herbs
• Enteric mucosal nourishment — supporting gut epithelial integrity, relevant to the gut-pancreatic axis in insulin-deficient lean diabetics

This difference in Basti delivery — decoction vs. oil — is not incidental but reflects the classical Ayurvedic pharmacological principle that Niruha Basti purifies and depletes, while Anuvasana Basti nourishes and sustains.⁴

2.4 Outcome Measures

Primary: Change in HbA1c (%) within each arm, and comparison of HbA1c change magnitude between CDC-SP and CDC-KP. Secondary: RBS (mg/dL), weight (kg), BMI (kg/m²), abdominal girth (cm), SBP and DBP (mmHg), heart rate (bpm). Post-treatment HbA1c target achievement (<6.5%, <7.0%, <8.0%) was compared between arms. Pearson correlation examined the relationship between baseline HbA1c and treatment response within each arm. A two-site comparison (Boisar vs. Palghar) was performed as an exploratory analysis.

2.5 Statistical Analysis

Data analyzed using Python (pandas, scipy.stats). Descriptive statistics as mean ± SD. Within-arm pre-post comparisons by paired Student's t-test (two-tailed; p<0.05). Between-arm comparison of change scores by independent Student's t-test. Pearson correlations for dose-response analyses. Subgroups with n<5 are reported descriptively.

3. RESULTS

3.1 Baseline Characteristics

Fifty-six patients were enrolled (37 male, 19 female; mean age 45.8 ± 8.6 years; range 32–67). As expected by design, CDC-KP patients had substantially lower BMI (22.40 ± 2.70 vs. 30.69 ± 6.36 kg/m²) and lower weight (64.80 ± 10.10 vs. 79.32 ± 14.75 kg) compared to CDC-SP, reflecting the BMI-based stratification criterion. CDC-KP patients had notably higher baseline HbA1c (9.89 ± 2.57% vs. 9.45 ± 1.89%), with 54.5% having HbA1c ≥9% and 27.3% having HbA1c ≥12% — suggesting a more severe baseline glycemic state despite lower adiposity, consistent with the lean diabetic's insulin-deficient pathophysiology.

Table 1. Baseline Characteristics — CDC-KP vs. CDC-SP

3.2 Primary Outcome: HbA1c Comparison — CDC-KP vs. CDC-SP

Both arms achieved statistically significant HbA1c reduction (Table 2). CDC-KP reduced HbA1c from 9.89 ± 2.57% to 8.12 ± 1.91% (Δ −1.77 ± 1.77%, p<0.001). CDC-SP reduced HbA1c from 9.45 ± 1.89% to 7.91 ± 1.75% (Δ −1.54 ± 1.58%, p<0.001). The between-group difference in HbA1c change was not statistically significant (−1.77 vs. −1.54%, p=0.660), confirming equivalent glycemic efficacy of both protocol arms despite their fundamentally different Basti formulations and divergent baseline BMI profiles.

Regarding post-treatment HbA1c target achievement, CDC-KP and CDC-SP showed comparable rates: HbA1c <7.0% was achieved by 30.0% of CDC-KP patients and 40.9% of CDC-SP patients; HbA1c <6.5% (ADA remission threshold⁶) by 20.0% and 27.3% respectively. The modest advantage of CDC-SP in achieving lower post-treatment targets likely reflects its lower baseline HbA1c (9.45% vs. 9.89%) rather than superior protocol efficacy.

Table 2. Primary Glycemic Outcomes — CDC-KP vs. CDC-SP (Paired Analysis)

3.3 Anthropometric and Hemodynamic Outcomes: The Divergent Pattern

The divergence between KP and SP becomes most pronounced in anthropometric outcomes (Table 3). CDC-SP produced significantly greater weight reduction (Δ −3.40 vs. −0.86 kg, between-group p=0.036) — a nearly 4-fold difference — and substantially greater abdominal girth reduction (Δ −4.50 vs. −1.94 cm). The between-group BMI difference showed a trend toward significance (p=0.172). Both arms showed non-significant blood pressure and heart rate changes, consistent with the Boisar-Palghar cohort's near-normal baseline hemodynamic parameters (mean DBP 82 mmHg, HR 87 bpm).

This pattern — equivalent HbA1c reduction with markedly different anthropometric responses — precisely matches the Ayurvedic theoretical prediction: Krisha Pramehi (lean diabetics) carry minimal adipose tissue to mobilize and respond to Brimhana treatment through metabolic-endocrine pathways (glycemic correction) rather than through body composition change. Sthula Pramehi (obese diabetics), by contrast, respond to Shodhana through both mechanisms simultaneously.

Table 3. All Clinical Outcomes — CDC-KP vs. CDC-SP

* Statistically significant between-group difference. † Borderline significant (p=0.055).

3.4 Dose-Response: Baseline HbA1c Predicts Response in CDC-KP

A strong inverse correlation was observed between baseline HbA1c and HbA1c change in CDC-KP patients (r=−0.670, p=0.001): lean diabetics with higher baseline HbA1c derived proportionally greater glycemic benefit from the protocol. This relationship was also present but weaker in CDC-SP (r=−0.502, p=0.017). The CDC-KP correlation is clinically actionable: it identifies severely hyperglycemic lean T2DM patients (HbA1c ≥10%) as the highest-benefit subpopulation for the Brimhana protocol — consistent with the classical principle that Brimhana therapy exerts the greatest restorative benefit when Dhatu Kshaya is most pronounced.

Table 4. Baseline HbA1c–Response Correlation and Post-Treatment Target Achievement

3.5 CDC-KP Cycle Analysis

Cycle-level analysis within the CDC-KP arm provides insight into the dose-response pattern of repeated Anuvasana Basti cycles (Table 5). CDC KP Base patients (n=9, lowest BMI 20.4 ± 8.1 kg/m²) achieved the greatest HbA1c reduction (Δ −2.94%) despite minimal weight change (Δ −0.61 kg), consistent with their lean constitution. CDC KP 1 patients (n=14, BMI 23.6 ± 2.9) achieved Δ −2.42% HbA1c with similarly modest anthropometric change. The single CDC KP 2 patient is purely descriptive (n=1).

Table 5. CDC-KP Cycle Analysis

CDC KP 2 (n=1): descriptive only — no statistical inference.

3.6 CDC-SP Cycle Analysis: Notable Weight Reduction in Cycle 2

CDC-SP showed a striking pattern in Cycle 2 patients (n=11): mean weight reduction of −11.6 kg and BMI reduction of −4.58 — the largest weight loss observed in any cycle subgroup across the entire six-clinic dataset. HbA1c reduction was also the highest for CDC-SP at this cycle (Δ −3.88%). This likely reflects patient selection (those motivated enough to return for a second cycle) and possibly cumulative dietary protocol adherence effects. CDC-SP Cycle 3 (n=3) also showed substantial weight loss (−9.1 kg) and RBS reduction (Δ −86.7 mg/dL), though statistical inference is not possible at n=3.

Table 6. CDC-SP Cycle Analysis

Cycle Base (n=4) and Cycle 3 (n=3): descriptive only.

3.7 Two-Site Comparison: Boisar vs. Palghar

Both sites showed significant glycemic and anthropometric improvements (Table 7). Palghar achieved numerically greater HbA1c reduction (Δ −2.20%, p=0.005) compared to Boisar (Δ −1.45%, p<0.001), and significant SBP reduction (Δ −11.0 mmHg, p=0.028) not seen at Boisar. Boisar showed better RBS response (Δ −57.3 mg/dL). The treatment group composition differed between sites: Boisar had proportionally more CDC-SP patients (57.1% vs. 42.9% in Palghar), which may partially explain the better anthropometric outcomes at Boisar.

Table 7. Two-Site Comparison: Boisar (n=42) vs. Palghar (n=14)